SCHEMBL19781806

SCHEMBL19781806

CC(C)Oc1ccc(-c2cnc3ccc(-c4ccc5c(ccn5C)c4)cn23)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRK5 P34947 1/20 0.48
PIK3CD O00329 2/20 0.46
PIK3R1 P27986 1/20 0.46
LRRK2 Q5S007 2/20 0.42
CLK1 P49759 4/20 0.41
KCNH2 Q12809 1/20 0.40
TUBB4A P04350 1/20 0.39
TUBB P07437 1/20 0.39
TUBA3C P0DPH7 1/20 0.39
TUBA1B P68363 1/20 0.39
TUBA4A P68366 1/20 0.39
TUBB4B P68371 1/20 0.39
TUBB3 Q13509 1/20 0.39
TUBB2A Q13885 1/20 0.39
TUBB8 Q3ZCM7 1/20 0.39
TUBA3E Q6PEY2 1/20 0.39
TUBA1A Q71U36 1/20 0.39
TUBA1C Q9BQE3 1/20 0.39
TUBB6 Q9BUF5 1/20 0.39
TUBB2B Q9BVA1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24460366 0.84 GRK5 (0.48) GRK5PIK3CDPIK3R1LRRK2CLK1
SCHEMBL19781539 0.83 CLK1 (0.47) CLK1KCNH2FLT3PIK3CAMTOR
SCHEMBL19781802 0.79 DYRK1A (0.48) LRRK2CLK1KCNH2PIK3CAMTOR
SCHEMBL19781133 0.79 RIPK2 (0.48) PIK3CDCLK1KCNH2PIK3CAMTOR
SCHEMBL19781810 0.78 KCNH2 (0.43) LRRK2CLK1KCNH2FLT3PIK3CA
SCHEMBL24460204 0.78 FYN (0.54) CLK1KCNH2FLT3PIK3CAMTOR
SCHEMBL24460223 0.77 BCL2 (0.44) CLK1KCNH2FLT3PIK3CAMTOR
SCHEMBL19781776 0.77 FYN (0.54) CLK1KCNH2PIK3CAMTORFYN
SCHEMBL19781168 0.77 SCN5A (0.50) CLK1KCNH2FLT3PIK3CAMTOR
SCHEMBL19781553 0.77 SCN5A (0.50) CLK1KCNH2FLT3PIK3CAMTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303569-A1 HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS ARISAN THERAPEUTICS INC. (US) 2023-09-28 US disclosed
US-20230303569-A1 HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS ARISAN THERAPEUTICS INC. (US) 2023-09-28 US disclosed
US-20230303569-A1 HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS ARISAN THERAPEUTICS INC. (US) 2023-09-28 US disclosed
US-11352328-B2 Heterocyclic compounds for the treatment of arenavirus ARISAN THERAPEUTICS INC. (US) 2022-06-07 US disclosed
WO-2022108849-A1 HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS ARISAN THERAPEUTICS INC. (US) 2022-05-27 WO disclosed
US-20190308938-A1 Heterocyclic Compounds for the Treatment of Arenavirus NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2019-10-10 US disclosed
WO-2018013430-A2 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION ARISAN THERAPEUTICS INC. (US) 2018-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303569-A1 HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS C3AR1, C9, C1R GRK5 2580/4885PIK3CD 3237/4885PIK3R1 1687/4885
US-11352328-B2 Heterocyclic compounds for the treatment of arenavirus C9, C1R, C1S GRK5 2169/4885PIK3CD 4682/4885PIK3R1 4570/4885
US-20190308938-A1 Heterocyclic Compounds for the Treatment of Arenavirus C9, C1R, C1S GRK5 2169/4885PIK3CD 4682/4885PIK3R1 4570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.